ArticleDiabetes care2021

Advancing Therapy in Suboptimally Controlled Basal Insulin-Treated Type 2 Diabetes: Clinical Outcomes With iGlarLixi Versus Premix BIAsp 30 in the SoliMix Randomized Controlled Trial.

Julio Rosenstock et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.